Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASK-PD0-CS002 Long-Term Follow-up of AB-1005 Gene Transfer
2025-522653-19-00Phase 4Authorised
- Sponsor
- AskBio
- Start
- Dec 2025
- Modality
- AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 2
01
Overview
Phase 4, open-label trial of ametefgene parvec in Parkinson's disease (PD) and striatonigral degeneration (MSA-P) (2 arms), sponsored by AskBio. Primary endpoint: Incidence and severity of adverse events. Planned start Dec 2025; status: authorised.
02
Drugs
ametefgene parvec
03
Conditions
Parkinson's disease (PD)striatonigral degeneration (MSA-P)
Beyond the preview
Go deeper on 2025-522653-19-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522653-19-00.